首页> 外文期刊>Pathology oncology research: POR >Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression
【24h】

Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression

机译:PTPN9的表达下调有助于人类肝细胞癌的生长和发展。

获取原文
获取外文期刊封面目录资料

摘要

Human hepatocellular carcinoma (HCC) is one of the most common malignant cancers, whose molecular mechanisms is remains largely. PTPN9 has recently been reported to play a critical role in breast cancer development. However, the role of PTPN9 in human HCC remains elusive. The present study aimed at investigating the potential role of PTPN9 in HCC. Western blot and immunohistochemistry were used to examine the expression of PTPN9 protein in HCC and adjacent non-tumorous tissues in 45 patients. Furthermore, Cell Counting Kit-8, flow cytometry and RNA interference experiments were performed to analyze the role of PTPN9 in the regulation of HCC cell proliferation. We showed that the expression level of PTPN9 was significantly reduced in HCC, compared with adjacent non-tumorous tissues. PTPN9 expression was inversely associated with Tumor size (P?=?0.014), serum AFP level (P?=?0.004) and Ki-67 expression. Low expression of PTPN9 predicted poor survival in HCC patients. Moreover, PTPN9 interference assay that PTPN9 inhibited cell proliferation in HepG2 cells. Cell apoptosis assay revealed that, silencing of PTPN9 expression significantly reduced cell apoptosis, compared with control ShRNA treatment group. Our results suggested that PTPN9 expression was down-regulated in HCC tumor tissues, and reduced PTPN9 expression was associated with worsened overall survival in HCC patients. Depletion of PTPN9 inhibits the apoptosis and promotes the proliferation of HCC cells.
机译:人肝细胞癌(HCC)是最常见的恶性肿瘤之一,其分子机制仍然很大。最近有报道称PTPN9在乳腺癌的发展中起着至关重要的作用。但是,PTPN9在人类HCC中的作用仍然难以捉摸。本研究旨在调查PTPN9在肝癌中的潜在作用。免疫印迹和免疫组化方法检测45例肝癌及癌旁组织中PTPN9蛋白的表达。此外,进行了细胞计数试剂盒8,流式细胞仪和RNA干扰实验,以分析PTPN9在调节HCC细胞增殖中的作用。我们显示,与邻近的非肿瘤组织相比,PTPN9的表达水平在肝癌中显着降低。 PTPN9表达与肿瘤大小( P ?=?0.014),血清AFP水平( P ?=?0.004)呈负相关。和Ki-67表达。 PTPN9的低表达预示肝癌患者生存不良。此外,PTPN9干扰试验表明PTPN9抑制HepG2细胞中的细胞增殖。细胞凋亡分析表明,与对照组ShRNA治疗组相比,PTPN9表达的沉默显着降低了细胞凋亡。我们的结果表明PTPN9表达在HCC肿瘤组织中下调,而PTPN9表达降低与HCC患者的整体生存期恶化有关。 PTPN9的消耗抑制凋亡并促进HCC细胞的增殖。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号